Stephen K. Burley, M.D., D.Phil., F.R.S.C.
Chief Scientific Officer and Senior Vice-President Research
SGX Pharmaceuticals, Inc.
San Diego, CA
Stephen Burley is the chief scientific officer of
SGX Pharmaceuticals, Inc., located in San Diego, California. SGX is an oncology
focused drug discovery and development company, with Troxatyl® in clinical trials
and multiple protein kinase inhibitors in preclinical development, including compounds
targeting imatinib resistant BCR-ABL. Prior to joining SGX, Burley was the Richard
M. and Isabel P. Furlaud professor and chief academic officer at The Rockefeller
University, and a full investigator in the Howard Hughes Medical Institute. He has
authored or coauthored more than 160 scholarly scientific articles. He is a fellow
of the Royal Society of Canada and of the New York Academy of Sciences. Burley received
an M.D. degree from Harvard Medical School in the joint Harvard-MIT Health Sciences
and Technology program and, as a Rhodes Scholar, received a D.Phil. in Molecular
Biophysics from Oxford University. He trained in internal medicine at the Brigham
and Women's Hospital, and did post-doctoral work with William N. Lipscomb at Harvard
University and Gregory A. Petsko at the Massachusetts Institute of Technology. With
William J. Rutter and others at the University of California, San Francisco and
The Rockefeller University, Burley co-founded Prospect Genomics, Inc., which was
subsequently acquired by SGX.